Ross Osborn
Stock Analyst at Cantor Fitzgerald
(1.82)
# 3,045
Out of 4,874 analysts
108
Total ratings
27%
Success rate
-6.83%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XGN Exagen | Maintains: Overweight | $8 → $7 | $6.77 | +3.40% | 6 | May 15, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $1.16 | +72.41% | 6 | May 15, 2025 | |
| NPCE NeuroPace | Reiterates: Overweight | $17 | $10.57 | +60.83% | 6 | May 14, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $17.92 | +39.51% | 9 | May 6, 2025 | |
| NNOX Nano-X Imaging | Maintains: Overweight | $12 → $9 | $5.25 | +71.43% | 11 | Apr 1, 2025 | |
| SMTI Sanara MedTech | Reiterates: Overweight | $46 | $28.07 | +63.88% | 6 | Mar 26, 2025 | |
| ELUT Elutia | Reiterates: Overweight | $8 | $1.81 | +341.99% | 10 | Mar 7, 2025 | |
| AXGN Axogen | Reiterates: Overweight | $24 | $10.25 | +134.15% | 3 | Mar 5, 2025 | |
| MDXG MiMedx Group | Reiterates: Overweight | $13 | $5.96 | +118.12% | 3 | Feb 27, 2025 | |
| CERS Cerus | Reiterates: Overweight | $4 | $1.32 | +203.03% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $9 | $7.79 | +15.53% | 7 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $3.98 | +126.13% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $4.77 | +340.25% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $7.75 | +106.45% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $5.84 | +139.73% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $96 | $84.54 | +13.56% | 1 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $1.22 | +186.89% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.76 | +228.95% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.44 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $3.54 | +41.24% | 2 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8.61 | $0.61 | +1,300.23% | 2 | Aug 18, 2023 |
Exagen
May 15, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $6.77
Upside: +3.40%
Lucid Diagnostics
May 15, 2025
Reiterates: Overweight
Price Target: $2
Current: $1.16
Upside: +72.41%
NeuroPace
May 14, 2025
Reiterates: Overweight
Price Target: $17
Current: $10.57
Upside: +60.83%
SI-BONE
May 6, 2025
Reiterates: Overweight
Price Target: $25
Current: $17.92
Upside: +39.51%
Nano-X Imaging
Apr 1, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $5.25
Upside: +71.43%
Sanara MedTech
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $28.07
Upside: +63.88%
Elutia
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $1.81
Upside: +341.99%
Axogen
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $10.25
Upside: +134.15%
MiMedx Group
Feb 27, 2025
Reiterates: Overweight
Price Target: $13
Current: $5.96
Upside: +118.12%
Cerus
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $1.32
Upside: +203.03%
Jan 16, 2025
Reiterates: Overweight
Price Target: $9
Current: $7.79
Upside: +15.53%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $3.98
Upside: +126.13%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $4.77
Upside: +340.25%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $7.75
Upside: +106.45%
Oct 23, 2024
Reiterates: Overweight
Price Target: $14
Current: $5.84
Upside: +139.73%
Oct 15, 2024
Initiates: Neutral
Price Target: $96
Current: $84.54
Upside: +13.56%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $1.22
Upside: +186.89%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.76
Upside: +228.95%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $1.44
Upside: -
Mar 1, 2024
Reiterates: Overweight
Price Target: $5
Current: $3.54
Upside: +41.24%
Aug 18, 2023
Reiterates: Neutral
Price Target: $8.61
Current: $0.61
Upside: +1,300.23%